Screener
Spyre Therapeutics, Inc. SYRE Available For Sale Securities Debt Securities Current
Available For Sale Securities Debt Securities Current at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and cash equivalents | $97,185 | $85,721 |
| Marketable securities | 644,282 | 670,812 |
| Prepaid expenses and other current assets | 22,486 | 21,248 |
| Total current assets | 763,953 | 777,781 |
| TOTAL ASSETS | $763,953 | $777,781 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s available for sale securities debt securities current?
- Spyre Therapeutics, Inc. (SYRE) reported available for sale securities debt securities current of $644.28M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s available for sale securities debt securities current changed year-over-year?
- Spyre Therapeutics, Inc.'s available for sale securities debt securities current increased by 24.8% year-over-year, from $516.33M to $644.28M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s available for sale securities debt securities current?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s available for sale securities debt securities current has grown at a 64.2% compound annual growth rate (CAGR), from $56.18M to $670.81M.
Ask your AI about Spyre Therapeutics, Inc.'s available for sale securities debt securities current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude